SRR602131
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.473
- ANGIOGENESIS+0.473
- IL6_JAK_STAT3_SIGNALING+0.462
- INFLAMMATORY_RESPONSE+0.447
- INTERFERON_ALPHA_RESPONSE+0.359
- TNFA_SIGNALING_VIA_NFKB+0.357
- COAGULATION+0.354
- INTERFERON_GAMMA_RESPONSE+0.335
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.332
- KRAS_SIGNALING_UP+0.293
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.683
- MYC_TARGETS_V2-0.528
- DNA_REPAIR-0.516
- MYC_TARGETS_V1-0.497
- ADIPOGENESIS-0.484
- HEDGEHOG_SIGNALING-0.414
- UNFOLDED_PROTEIN_RESPONSE-0.394
- PROTEIN_SECRETION-0.385
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.359
- PEROXISOME-0.318
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR608598 | GTEX | — | 0.966 |
| 2 | SRR615020 | GTEX | — | 0.961 |
| 3 | SRR1474795 | GTEX | — | 0.960 |
| 4 | SRR655590 | GTEX | — | 0.957 |
| 5 | SRR1335047 | GTEX | — | 0.951 |
| 6 | SRR818270 | GTEX | — | 0.949 |
| 7 | SRR1361795 | GTEX | — | 0.946 |
| 8 | SRR601201 | GTEX | — | 0.946 |
| 9 | SRR1358561 | GTEX | — | 0.946 |
| 10 | SRR613114 | GTEX | — | 0.945 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.473 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.473 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.462 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.447 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.359 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.357 | Inavolisib | — uncovered |
| COAGULATION | 0.354 | Binimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.335 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.332 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.293 | Inavolisib | — uncovered |
| MYOGENESIS | 0.287 | Inavolisib | — uncovered |
| COMPLEMENT | 0.284 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.283 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.229 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.228 | Inavolisib | — uncovered |
| APOPTOSIS | 0.181 | Idelalisib | — uncovered |
| HYPOXIA | 0.162 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.144 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.123 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.079 | Idelalisib | — uncovered |